

## Antihistamine Oral and Intranasal

Generic Drug	Trade Name example	Metabolites if significant (T1/2 in hours of product or metabolite)	Tmax hrs (metabolite)	Skin test suppression mean (max) days	Sedation/Somnolence or CNS impairment (control)	Dosage forms	Age Limit	Adult dose
<b>2<sup>nd</sup> Generation</b>								
acrivastine <sup>d</sup>	Semprex-D	(1.4-3.1) <sup>648</sup>	1.15 <sup>649</sup> 1.4 <sup>648</sup>	~ 3, t <sup>1/2</sup> =1.7 hr	8% <sup>650</sup> 12(6) <sup>PI</sup>	8 mg	12	8 mg qid
azelastine hcl	Astelin nasal	Desmethylazelastine (22) PI	2.5 <sup>651</sup> .25 <sup>**335</sup>	2 <sup>651, 652</sup>	11.5 (5.4) <sup>PI</sup>	137mcg/sp.	5	2 sp./nostril bid
cetirizine <sup>d</sup>	Zyrtec	None (7-11) <sup>648</sup>	1.0 ± 0.5 <sup>651</sup>	3 <sup>651</sup>	14 (10) <sup>PI</sup>	5, 10 mg 5 mg/5 mL	6 mo	5-10 mg q day
desloratadine <sup>d</sup>	Clarinex	3 hydroxy desloratadine (7.8± 4.2) <sup>648</sup>	3.17 (4.76) <sup>653</sup>	~ 7 (T <sub>1/2</sub> =21-31hr)	2.1(1.8) <sup>PI</sup>	5 mg 2.5 mg/5 mL	6 mo	5 mg q day
fexofenadine <sup>d</sup>	Allegra	None (14.4-14.6) <sup>648</sup>	2.6 <sup>651</sup>	2 <sup>651</sup>	1.3(.9) <sup>PI</sup>	30, 60, 180 mg 30 mg/5 mL	2	180 mg q day or 60 mg bid
levocetirizine	Xyzal	None (7± 1.5) <sup>648</sup>	.9 <sup>654</sup> 1.25 <sup>PI</sup>	U/K	6 (2) <sup>PI</sup>	5 mg	6	5 mg q day
loratadine <sup>d</sup>	Claritin	Descarboethoxy loratadine (7.8± 4.2) <sup>648</sup>	1.2 ± 0.3 <sup>651</sup> (1.5 ± 0.7) <sup>651</sup>	7 <sup>651</sup>	8(6) <sup>PI</sup>	10 mg 5 mg/5 mL	2	10 mg q day
Olopatadine hydrochloride	Patanase nasal	No major metabolites (8-12) <sup>PI</sup>	.5-1.0 <sup>PI</sup>	U/K	0.9(0.3) <sup>PI</sup>	665 mcg/sp.	12	2 sp./nostril bid
<b>1<sup>st</sup> Generation</b>								
brompheniramine	Dimetapp	24.9±9.3 <sup>655</sup>	4 <sup>656</sup>	>2 <sup>655</sup> , 4 <sup>657</sup>	24 (5) <sup>317</sup>	12 mg 1 mg/5 mL	2	1-2 bid
chlorpheniramine <sup>d</sup>	Chlor-Trimeton	Mono & didesmethyl chlorpheniramine (27.9± 8.7) <sup>648</sup>	2-6 <sup>658</sup> , 2.8 <sup>648</sup>	3 <sup>659</sup> (6 <sup>660</sup> )	45% <sup>656</sup>	4, 8, 12 mg 2mg/5mL	2	4 mg qid
clemastine <sup>d</sup>	Tavist	(21.3± 11.6) <sup>661</sup>	4.77 +/- 2.26 <sup>661</sup>	5 <sup>662</sup> (10 <sup>662</sup> )	14 (1.5) <sup>663</sup>	1.34, 2.68 mg .67 mg/5ml	6	1.34 mg bid to tid
cyproheptadine	Periactin	(16) <sup>664</sup>	4 <sup>665</sup>	9 <sup>666</sup> (11 <sup>666</sup> )	8-50 <sup>667</sup>	4 mg 2 mg/5 mL	2	4 mg tid
diphenhydramine	Benadryl	Nordiphenhydramine (9.2±2.5) <sup>648</sup>	2.6 <sup>668, 669</sup> , 1.7±1.0 <sup>648</sup>	2 <sup>659</sup> (5 <sup>659</sup> )	50% <sup>656</sup>	25, 50 12.5 mg/mL	2	25-50 mg qid
hydroxyzine	Atarax	(20± 4.1) <sup>648</sup>	2.1 ± 0.4 <sup>648</sup>	5 <sup>659</sup> (8 <sup>659</sup> )	80% <sup>656</sup>	10, 25, 50, 100 mg 10 mg/5 mL	All ages	25 mg qid
promethazine	Phenergan	Promethazine sulfoxide & N-desmethylpromethazine (9-16) PI	4.4 <sup>670</sup>	3 <sup>659</sup> (5 <sup>659</sup> )	60-73 <sup>671</sup>	12.5, 25, 50 mg 6.25 mg/5 mL	2	25 mg qid
triprolidine	Actifed	(3.2) PI	2.0 <sup>672</sup>	3 <sup>659sim649, 655, 656</sup> (7 <sup>[7]</sup> )	10-25%			

D= available with decongestant \*\* Onset of action, not tmax PI=package insert

Adapted from: Wallace, D., et al., *The diagnosis and management of rhinitis: an updated practice parameter*. J Allergy Clin Immunol, 2008. 122(2 Suppl): p. S1-84